{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T17:49:40Z","timestamp":1768585780522,"version":"3.49.0"},"reference-count":12,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Alagille syndrome (ALGS) is a genetic disorder primarily affecting the liver, often leading to cholestasis and pruritus. Ileal Bile Acid Transporter inhibitors (IBATi), such as maralixibat, have shown promise in controlling pruritus and potentially modifying disease progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>We report two patients with ALGS treated with maralixibat. Case 1 involved a 10-days-old newborn presenting with cholestasis, jaundice, and acholic stools. Genetic testing confirmed a pathogenic JAG1 mutation. Despite preserved liver function, the patient was evaluated for liver transplantation (LT) due to severe pruritus and portal hypertension. Maralixibat initiation led to marked improvement in pruritus, serum bile acids, bilirubin, and cholesterol. Liver biopsies performed 13 months apart demonstrated fibrosis regression from cirrhosis to stage F2. Elastography showed decreased liver stiffness, reduced splenomegaly, and improved platelet counts. Liver enzymes transiently increased, but treatment continued without dose adjustment. Case 2 involved a 15-years-old female with moderate portal hypertension and mild pruritus. After 24 months of maralixibat, pruritus resolved completely, serum bile acids decreased, liver stiffness and splenomegaly improved, and platelet counts increased. Liver enzymes remained mildly elevated without requiring treatment modification. These findings suggest maralixibat may improve portal hypertension and hepatic injury, even in patients with less severe biochemical abnormalities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In ALGS, maralixibat treatment improved pruritus, lowered serum bile acids, and suggested potential benefits on fibrosis and portal hypertension, indicating a possible role beyond symptomatic relief.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2025.1707258","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T06:32:44Z","timestamp":1768545164000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond pruritus in Alagille syndrome: potential effects of maralixibat on fibrosis and portal hypertension\u2013insights from two case studies"],"prefix":"10.3389","volume":"12","author":[{"given":"Jes\u00fas","family":"Quintero-Bernabeu","sequence":"first","affiliation":[{"name":"Pediatric Hepatology and Liver Transplant Unit, Department of Pediatrics, Vall d\u2019Hebron Barcelona Hospital Campus, ERN Rare Liver ERN TransplantChild","place":["Barcelona, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Padr\u00f3s-Fornieles","sequence":"additional","affiliation":[{"name":"Pediatric Hepatology and Liver Transplant Unit, Department of Pediatrics, Vall d\u2019Hebron Barcelona Hospital Campus, ERN Rare Liver ERN TransplantChild","place":["Barcelona, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Mercadal-Hally","sequence":"additional","affiliation":[{"name":"Pediatric Hepatology and Liver Transplant Unit, Department of Pediatrics, Vall d\u2019Hebron Barcelona Hospital Campus, ERN Rare Liver ERN TransplantChild","place":["Barcelona, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauricio","family":"Larrarte-King","sequence":"additional","affiliation":[{"name":"Pediatric Hepatology and Liver Transplant Unit, Department of Pediatrics, Vall d\u2019Hebron Barcelona Hospital Campus, ERN Rare Liver ERN TransplantChild","place":["Barcelona, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Mameli","sequence":"additional","affiliation":[{"name":"Pediatric Hepatology and Liver Transplant Unit, Department of Pediatrics, Vall d\u2019Hebron Barcelona Hospital Campus, ERN Rare Liver ERN TransplantChild","place":["Barcelona, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar","family":"Miserachs-Barba","sequence":"additional","affiliation":[{"name":"Pediatric Hepatology and Liver Transplant Unit, Department of Pediatrics, Vall d\u2019Hebron Barcelona Hospital Campus, ERN Rare Liver ERN TransplantChild","place":["Barcelona, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lis","family":"Vidal-Valdivia","sequence":"additional","affiliation":[{"name":"Pediatric Hepatology and Liver Transplant Unit, Department of Pediatrics, Vall d\u2019Hebron Barcelona Hospital Campus, ERN Rare Liver ERN TransplantChild","place":["Barcelona, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Andr\u00e9s","family":"Molino-Gahete","sequence":"additional","affiliation":[{"name":"Department of Pediatric Surgery, Vall d\u2019Hebron Barcelona Hospital Campus","place":["Barcelona, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Moreno-Galdo","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Vall d\u2019Hebron Barcelona Hospital Campus","place":["Barcelona, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/hep.32761","article-title":"Natural history of liver disease in a large international cohort of children with Alagille syndrome: results from the GALA study.","volume":"77","author":"Vandriel","year":"2023","journal-title":"Hepatology."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1002\/humu.23879","article-title":"Alagille syndrome mutation update: comprehensive overview of JAG1 and NOTCH2 mutation frequencies and insight into missense variant classification.","volume":"40","author":"Gilbert","year":"2019","journal-title":"Hum Mutat."},{"key":"B3","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S2468-1253(24)00074-8","article-title":"Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial.","volume":"9","author":"Ovchinsky","year":"2024","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/S0140-6736(21)01256-3","article-title":"Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study.","volume":"398","author":"Gonzales","year":"2021","journal-title":"Lancet."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1097\/HEP.0000000000000727","article-title":"Event-free survival of maralixibat-treated patients with Alagille syndrome compared to a real-world cohort from GALA.","volume":"79","author":"Hansen","year":"2024","journal-title":"Hepatology."},{"key":"B6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40271-017-0266-4","article-title":"Development of a novel tool to assess the impact of itching in pediatric cholestasis.","volume":"11","author":"Kamath","year":"2018","journal-title":"Patient."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.12688\/f1000research.12449.1","article-title":"Recent advances in understanding bile acid homeostasis.","volume":"6","author":"Chiang","year":"2017","journal-title":"F1000Research."},{"key":"B8","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1097\/MPG.0000000000001958","article-title":"Systematic review: the epidemiology, natural history, and burden of Alagille syndrome.","volume":"67","author":"Kamath","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"B9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.mam.2017.06.001","article-title":"Mechanisms of bile acid mediated inflammation in the liver.","volume":"56","author":"Li","year":"2017","journal-title":"Mol Aspects Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1053\/jhep.2001.22702","article-title":"Bile acid-induced rat hepatocyte apoptosis is inhibited by antioxidants and blockers of the mitochondrial permeability transition.","volume":"33","author":"Yerushalmi","year":"2001","journal-title":"Hepatology."},{"key":"B11","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ajpath.2010.11.026","article-title":"Bile acids induce inflammatory genes in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis.","volume":"178","author":"Allen","year":"2011","journal-title":"Am J Pathol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"100276","DOI":"10.1016\/j.jhepr.2021.100276","article-title":"Boosting mitochondria activity by silencing MCJ overcomes cholestasis-induced liver injury.","volume":"3","author":"Iruzubieta","year":"2021","journal-title":"JHEP Rep."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1707258\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T06:32:45Z","timestamp":1768545165000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1707258\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":12,"alternative-id":["10.3389\/fmed.2025.1707258"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1707258","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"article-number":"1707258"}}